Cells, published by MDPI in Switzerland, is a leading open-access journal that has been disseminating groundbreaking research in the fields of Biochemistry, Genetics, and Molecular Biology since its inception in 2011. With an impressive E-ISSN of 2073-4409, the journal boasts a strong impact factor and ranks in the 84th percentile for Scopus ratings, underscoring its significance in advancing scientific knowledge. As a Q1-ranked journal in both 2023 and 2020, it serves as a premier platform for researchers, professionals, and students eager to explore innovative findings and methodologies. By providing unrestricted access to high-quality research, Cells plays a pivotal role in facilitating collaboration and inspiration within the global scientific community, making it an indispensable resource for anyone interested in cutting-edge discoveries in cellular biology.

Biomedical Research and Therapy is a pioneering journal published by BIOMEDPRESS, dedicated to the field of biomedical sciences. With its ISSN 2198-4093, this journal aims to disseminate high-quality research and innovative therapies that advance knowledge in biomedical research. Although it operates on a non-open access model, it provides crucial insights into various topics such as drug discovery, disease mechanisms, regenerative medicine, and clinical applications. The journal's rigorous peer-review process ensures the publication of critical findings and methodologies, making it a vital resource for researchers, practitioners, and students interested in the constantly evolving landscape of biomedical research. With converged years from 2020 to 2024 and an emerging reputation in its field, Biomedical Research and Therapy is positioned to contribute significantly to the global scientific community, enriching the discourse around therapeutic advancements and biomedical innovations.

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

Molecular Medicine Reports, an esteemed academic journal published by Spandidos Publications Ltd, serves as a vital platform for the dissemination of cutting-edge research in the field of molecular medicine. Established in 2008, this journal has rapidly ascended in prominence, currently positioned within the Q2 and Q3 quartiles across various critical categories including Biochemistry, Cancer Research, and Genetics, reflecting its significant impact and scholarly contributions. With an impressive Scopus ranking in multiple disciplines, including an 87th place in Oncology, it is recognized for publishing rigorous, peer-reviewed articles that bridge the gap between laboratory research and clinical applications. The journal’s commitment to advancing knowledge in molecular medicine is evident through its focus on innovative therapeutic approaches, genetic research, and oncological studies, catering to a diverse readership of researchers, professionals, and students in the biomedical field. Though not an open-access publication, it provides invaluable insights and fosters collaboration in the scientific community from its base in Athens, Greece.

Journal of Biomedical Research, published by Nanjing Medical University in China, is a prominent platform for groundbreaking discoveries in the fields of Biochemistry, Genetics, and Molecular Biology, as well as Medicine. With an ISSN of 1674-8301 and an E-ISSN of 1876-4819, the journal offers a vital opportunity for researchers, professionals, and students to disseminate insightful research findings. Although not currently available as an open access journal, its inclusion in the second quartile of both Biochemistry and Medicine categories underscores its growing influence and commitment to high-quality scholarship, as evidenced by its historical compliance with Scopus rankings prior to 2009. By fostering an interdisciplinary approach, the Journal of Biomedical Research aims to bridge gaps in current biomedical understanding and encourages innovative research that can lead to significant contributions in improving health outcomes. Its editorial policies guarantee rigorous peer review, making it a trusted source of knowledge in the biomedical community.

Biomed Research International is a prominent open access journal published by HINDAWI LTD, dedicated to advancing the field of biomedical research. With its ISSN 2314-6133 and E-ISSN 2314-6141, this journal has been a significant contributor to the scientific community since its inception in 2013, making scholarly work accessible to a global audience. The journal's scope encompasses a range of disciplines, including biochemistry, genetics, molecular biology, immunology, microbiology, and medicine, reflecting its commitment to interdisciplinary research. Ranked in the Q2 quartile as of 2023 across several relevant categories, Biomed Research International is recognized for its high-quality publications that foster innovation and collaboration in biomedical studies. Researchers, professionals, and students looking to share and gain insights into cutting-edge biomedical discoveries will find this journal an essential resource. With a focus on rapid dissemination of research findings, the journal serves as a vital platform for academics to engage with contemporary issues in health and disease, ultimately contributing to the advancement of medical science.

IN VIVO is a prestigious academic journal published by the International Institute of Anticancer Research, dedicated to advancing the fields of biochemistry, genetics, molecular biology, cancer research, and pharmacology. With its ISSN 0258-851X and E-ISSN 1791-7549, this journal has been a key contributor to innovative research since its inception in 1987, providing a crucial platform for the dissemination of significant findings in its scope. With an impressive impact reflected in its quartile rankings (Q2 in Biochemistry, Genetics and Molecular Biology and Medicine; Q3 in Cancer Research and Pharmacology), IN VIVO reaches a global audience comprising researchers, health professionals, and students. Although it operates on a subscription basis, the journal’s commitment to scientific excellence and rigorous peer review ensures that all published works maintain high quality and relevance. Notably positioned in Scopus ranks within the 36th to 59th percentiles across various categories, IN VIVO continues to be a vital resource for cutting-edge research and developments, solidifying its importance within the scientific community.

Molecular Biomedicine is a prestigious peer-reviewed journal published by SpringerNature, dedicated to advancing the fields of molecular biology and molecular medicine. With a commendable Q1 ranking in both categories for 2023, this journal stands out for its rigorous exploration of the biochemical processes underlying health and disease. Operating out of Germany, Molecular Biomedicine aims to provide comprehensive insights into cutting-edge research, facilitating interdisciplinary collaboration among researchers, healthcare professionals, and students alike. The journal's impact is reflected in its Scopus rankings, placing it in the upper echelons of the fields of biochemistry, genetics, and molecular biology. As an open access platform, it commits to disseminating knowledge widely, ensuring that pivotal discoveries are accessible to all. Researchers looking to publish in a dynamic environment that prioritizes innovation and application in the biomedical sciences will find Molecular Biomedicine an ideal outlet for their work.

GROWTH FACTORS, published by Taylor & Francis Ltd, is a prestigious journal dedicated to advancing the field of cell biology, clinical biochemistry, and endocrinology. With an ISSN of 0897-7194 and an E-ISSN of 1029-2292, this journal has served as a vital platform for the dissemination of groundbreaking research since its inception in 1988. Although it operates without an Open Access model, GROWTH FACTORS focuses on providing high-quality, peer-reviewed articles that explore the intricate roles of growth factors in biological processes and their implications in health and disease. Holding a Q4 ranking in Cell Biology and Q3 rankings in Clinical Biochemistry and Endocrinology according to the 2023 category quartiles, the journal is well-regarded in its field and plays a crucial role in informing researchers, professionals, and students alike about the latest findings and innovations in these areas. The journal's commitment to fostering scientific dialogue ensures that it remains a key resource for those looking to enhance their understanding of growth factors and their applications in clinical settings.

Cell Discovery, published by SPRINGERNATURE, is a premier open access journal in the dynamic fields of Biochemistry, Cell Biology, Genetics, and Molecular Biology. Since its inception in 2015, this journal has established itself as a key platform for disseminating high-impact research and is recognized with a Q1 ranking across all its core categories for the year 2023. With its remarkable Scopus rankings—7th in Genetics, 9th in Biochemistry, 13th in Molecular Biology, and 15th in Cell Biology—Cell Discovery positions itself among the elite journals in life sciences, showcasing the most innovative breakthroughs and comprehensive reviews. Based in the United Kingdom, this journal operates under an open access model, ensuring that groundbreaking discoveries are readily available to researchers, professionals, and students around the globe. With a commitment to advancing scientific knowledge, Cell Discovery welcomes contributions that push the frontiers of our understanding in cellular and genetic sciences.